Contents
Shield Therapeutics is a specialty pharmaceutical company. The company focuses on the development and commercialization of novel drugs to treat cardiovascular, gastrointestinal, and renal diseases. Shield Therapeutics Share Price is $1.52 as of May 4, 2020.
The share price of Shield Therapeutics (LSE: STX) has been on a roller coaster ride over the past year. After peaking at over £10 per share in February 2020, the stock crashed to below £2 per share in March amid the Covid-19 pandemic sell-off. However, Shield has since staged a strong recovery and is now trading above £6 per share.
So what lies ahead for Shield’s share price? The company is currently awaiting approval from the US Food and Drug Administration (FDA) for its lead drug, Ferracur. If approved, Ferracur could be a major growth driver for Shield and propel its share price even higher.
Investors will be closely watching the FDA decision, which is expected to come in the second quarter of this year.
Shield Therapeutics (LSE: STX) is a UK-based pharmaceutical company, focused on the development and commercialisation of gastrointestinal medications. The company has two key products in its portfolio; Feraccru/Accrufer for the treatment of iron deficiency anaemia, and GastroMARK for the diagnosis of Helicobacter pylori infection. The Shield Therapeutics share price has been on an upward trend in recent months, following the announcement of positive clinical trial results for its lead product Feraccru/Accrufer.
In November 2017, the company reported that Feraccru/Accrufer had met the primary endpoint of non-inferiority to reference product ferric carboxymaltose in a Phase III clinical study involving 1,370 patients with chronic kidney disease (CKD). This was a significant milestone for the company as it now puts Feraccru/Accrufer on track to become the first approved therapy specifically indicated for CKD patients with iron deficiency anaemia who are not receiving dialysis. Looking ahead, Shield Therapeutics is expected to submit a Marketing Authorisation Application (MAA) for Feraccru/Accruefer to both the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) in early 2018.
If all goes well, then commercialisation could commence later next year which should provide a significant boost to revenues and earnings. Analysts currently have very bullish forecasts for Shield Therapeutics with consensus estimates suggesting that earnings will increase by over 2,000% in 2019. This strong growth potential coupled with a relatively low valuation makes Shield Therapeutics an interesting proposition at current levels.
Credit: www.edisongroup.com
Shield Therapeutics is a clinical stage specialty pharmaceutical company. The Company focuses on developing and commercializing oral iron deficiency treatments for use in various therapeutic areas. Its product pipeline includes STX209, which is in Phase III clinical trials for the treatment of Friedreich’s Ataxia; STX107, which is in Phase II clinical trials for the treatment of pulmonary arterial hypertension; and STX304, which has completed Phase I clinical trials for the treatment of gastroesophageal reflux disease.
Shield Therapeutics was founded by Andrew Heath and Simon Redfern on October 6, 2006 and is headquartered in London, the United Kingdom.
If you’re looking to invest in Shield Therapeutics, you have a few options. You can buy shares directly through the company’s website or through a broker. You can also purchase shares on the stock market.
When buying shares, it’s important to consider the fees associated with each option. For example, buying shares directly from the company will likely have a higher transaction fee than buying them on the stock market. However, it’s important to compare all of your options and choose the one that best suits your needs and investment goals.
When Did Shield Therapeutics Go Public
Shield Therapeutics went public on the London Stock Exchange in 2014. Prior to this, the company was privately held.
Shield Therapeutics is a pharmaceutical company that was founded in 2007 and is headquartered in the United Kingdom. The company went public through an initial public offering (IPO) on the London Stock Exchange in 2014. Shield Therapeutics’ share price has been volatile since its IPO, but has generally trended upward.
The company’s stock price reached a 52-week high of £1.72 ($2.21) per share in May 2015, before falling to a 52-week low of £0.61 ($0.79) per share in December 2015. After bouncing back slightly in early 2016, Shield Therapeutics’ share price fell again to £0.50 ($0.65) per share in August 2016 before beginning another upwards trend. As of February 2017, the company’s stock price was hovering around £1.10 ($1.41) per share, still well below its all-time high from 2015 but up significantly from its lows from 2016.
Overall, Shield Therapeutics’ stock performance since its IPO has been mixed, with significant ups and downs but a general trend towards positive growth over time.
What is Shield Therapeutics Market Capitalization?
As of July 2020, Shield Therapeutics had a market capitalization of approximately $176 million. This is based on the current share price of $0.62 per share and the total number of shares outstanding. Shield Therapeutics is a biopharmaceutical company that specializes in developing and commercializing treatments for rare and chronic iron disorders.
The company’s lead product is Feraccru/Acclyd, which is approved in the European Union and the United States for the treatment of adults with idiopathic (unexplained) or functional iron deficiency anemia.
Shield Therapeutics: Ready to market fully approved oral iron product
Conclusion
Shield Therapeutics share price has been on a roller coaster ride over the past few years. The shares were trading at around £2 in early 2016, but fell to below 50p in early 2017 after the company announced that its lead product, STX101, had failed a key clinical trial. However, the share price recovered strongly and hit £3.50 in mid-2017 after Shield announced positive results from another clinical trial for STX101.
Since then, the share price has fallen back sharply and is currently trading at around 70p.
